The Gene Therapy R&D Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Diversification of Technical Risks is a Key Strategy for Winning in the Gene Therapy R&D Market
The majority of the biotechnology firms associated with gene therapies are established across a special technology platform i.e., novel viral capsid that could have favoured acceptance in an organ system. Most of them continue to de-risk the technology as soon as possible, with the underlying technology platform that gave birth to the gene therapy candidates often being the main feature across chosen indications. This focuses risk on the technology platform & exposes the company to a catastrophic event that would have a negative impact on the entire portfolio. When it comes to this challenge, early-stage gene therapy firms often lack this choice; and once the newly founded technology achieves traction, executives will often follow adjacent plans that diversify risk & optimize prospects for the company. Companies working on gene therapies may evolve distinct viral delivery vectors or technologies for in vivo & ex vivo applications. Furthermore, balancing spending levels between developed and emerging channels, as well as deciding whether to implement new innovations in-house or obtain them from outside sources, is difficult. Importantly, strategic decisions about technology should be matched with strategic decisions about indication mix to ensure a clear future path.
400 million People Suffer from One or More of Over 7,000 Rare Diseases
About 400 million people globally suffer from one or more of over 7,000 rare diseases reported. Rare disease affects between 3.5% and 5.9% of the world's population. The cause of 72% of rare diseases is hereditary, while others are triggered by pathogens (bacterial or viral), asthma, and environmental conditions, or are degenerative and proliferative in nature. Approximately, 70% of genetic rare diseases begin in childhood. Symptoms that are relatively normal can obscure underlying unusual disorders, resulting in misdiagnosis and treatment delays. The lack of loss of mobility caused by the chronic, worsening, degenerative, and often life-threatening manifestations of the condition has a significant effect on the patient's quality of life. Thus, the rising number of rare disease patients around the world is anticipated to drive the gene therapy application in this segment during the forecast period.
The costliest medication in the world right now is Zolgensma, which treats spinal muscular atrophy, a rare hereditary illness that harms nerve cells and causes muscle degeneration. The life-saving medication's one-time treatment for a young child costs $2.1 million. While Zolgensma's excessive cost is an incongruity at present times, there will be several cell & gene therapies available over the next ten years, with prices ranging from thousands to millions of dollars for a single dose. By 2025, the FDA is anticipated to approve 10-20 cell & gene therapies annually.
Asia-Pacific Region Remains a Hub for Advanced Therapy Medicinal Products
With the many legislative initiatives put forth by the governments to promote innovation, research, and development in Asia-Pacific, the area remains a hub for advanced therapy medicinal products. Over the course of the projected period, this is expected to propel market expansion. A*STAR's Bioprocessing Technology Institute (BTI) and WuXi Advanced Therapies, a fully owned subsidiary of WuXi AppTec, established a new agreement in May 2022 to introduce WuXi ATU's unique Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology in the Asia-Pacific area. WuXi ATU will provide the resources, tools, funds, and training necessary to advance the development and commercialization of TESSA technology in Singapore as part of this partnership. BTI will support WuXi ATU in its research and development of cell and gene therapy in Singapore by providing research skills, facilities, and access to its network of partners.
What Are These Questions You Should Ask Before Buying A Market Research Report?
• How is the gene therapy R&D market evolving?
• What is driving and restraining the gene therapy R&D market?
• How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each gene therapy R&D submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the gene therapy R&D projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implication of gene therapy R&D projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
• Where is the gene therapy R&D market heading? And how can you ensure you are at the forefront of the market?
• What can be the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path? C-suite?
You need to discover how this will impact the Gene Therapy R&D Market today, and over the next 10 years:
• Our 461-page report provides 169 tables and 228 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• Contains in-depth analysis of global, regional and national sales and growth
• Highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the Gene Therapy R&D Market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), PEST analysis, Porter’s Five Forces and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U’ are discussed in this report.
Segments Covered in the Report
Disease
• Cancer
• Rare Diseases
- Oncologic
- Non-oncologic
• Cardiovascular Diseases
• Ophthalmic Diseases
• Haematology
• Neurological
• Diabetes Mellitus
• Other Diseases
Vector
• Viral
- Retrovirus
- Adenovirus
- AAV
- Lentivirus
- Others
• Non-viral
- Naked DNA
- Gene Gun
- Electroporation
- Lipofection
Techniques
• Gene Augmentation Therapy
• Gene Replacement Therapy
Participants
• Small/Medium Pharma & Biotech
• Universities & Research Institutes
• Hospitals
• Government & Public Bodies
• Big Pharma
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Gene Therapy R&D Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Astellas Pharma Inc.
• American Gene Technologies
• Applied Genetic
• Bayer
• Benitec BioPharma
• Biogen
• Bluebird Bio
• Bristol Myers Squibb
• Calimmune, Inc. (CSL Behiring)
• Cellectis
• F. Hoffmann-La Roche Ltd.
• GeneQuine Biotherapeutics
• GenSight Biologics
• Gilead Lifesciences, Inc.
• Novartis AG
• OCUGEN, INC.
• Orchard Therapeutics
• Oxford Biomedica
• Pfizer, Inc.
• REGENXBIO Inc.
• Sangamo Therapeutics, Inc.
• Sanofi
• Sarepta Therapeutics, Inc.
• Spark Therapeutics (Subsidiary of Roche)
• Takeda Pharmaceuticals
• Taysha GTx
• Transgene
• UniQure NV
• Voyager Therapeutics
• ViGeneron.
Overall world revenue for Gene Therapy R&D Market, 2022 to 2032 in terms of value the market will surpass US$2,126.3 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Gene Therapy R&D Market, 2022 to 2032 Market report helps you?
In summary, our 460+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Gene Therapy R&D Market, 2022 to 2032 Market, with forecasts for disease, vector, techniques, and participants size each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 5 regional and 18 key national markets – See forecasts for the Gene Therapy R&D Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 30 of the major companies involved in the Gene Therapy R&D Market, 2022 to 2032 Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Gene Therapy R&D Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.
'
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Gene Therapy R&D Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Drivers
3.3.1 Robust Gene Therapy Pipeline to Boost Growth
3.3.2 Technological Advancements to Fuel Market Growth
3.3.3 Increasing Investments by Major Players
3.3.3.1 Financings by Deal Type, 2021
3.3.3.2 Financings by Deal Type, 2020
3.3.4 Growing Prevalence of Targeted Diseases Treatment
3.4 Restraints/Challenges
3.4.1 Cell & Gene Therapies Target Specific Diseases
3.4.2 High Cost to Stifle Gene Therapy R&D Growth
3.4.3 Regulatory Scenarios to Challenge Industry Growth
3.5 Opportunities
3.5.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
3.5.2 Facility Expansion Anticipated to Offer Lucrative Growth Prospects
3.6 COVID-19 Impact Analysis
3.7 Porter’s Five Forces Analysis
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Competitive Rivalry
3.7.4 Threat of Substitute Products
3.7.5 Threat of New Entrants
3.8 PEST Analysis
3.8.1 Political Factors Impacting Gene Therapy R&D Market
3.8.2 Economic Factors Impacting Gene Therapy R&D Market
3.8.3 Social Factors Impacting Gene Therapy R&D Market
3.8.4 Technological Factors Impacting Gene Therapy R&D Market
3.9 Pipeline Analysis
3.9.1 Projected Launch Year, 2022
3.9.2 Projected Launch Year, 2023
3.9.3 Projected Launch Year, 2024
3.9.4 Projected Launch Year, 2025
3.9.5 Gene Therapy Pipeline Assets Forecast till 2026
3.9.6 Clinical Trials Activity by Key Areas
3.9.6.1 Industry Sponsored Trials by Phase
3.9.6.2 Academic and Government Sponsored Trials by Phase
3.9.6.3 Rare Diseases Clinical Activity by Indication
3.9.6.4 Prevalent Diseases Clinical Activity by Indication
3.9.6.5 Next-Gen Therapies Competition by Region
3.9.6.6 Indications With Significant Clinical Activity
4 Gene Therapy R&D Market Analysis by Disease
4.1 Key Findings
4.2 Disease Segment Growth Prospects
4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease
4.4 Cancer
4.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Rare Diseases
4.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
4.5.3 Rare Diseases Segment Market Forecast by Type, 2022-2032 (US$ Mn)
4.6 Cardiovascular Diseases
4.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.6.2 Market Share by Region, 2022 & 2032 (%)
4.7 Ophthalmic Diseases
4.7.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.7.2 Market Share by Region, 2022 & 2032 (%)
4.8 Hematology
4.8.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.8.2 Market Share by Region, 2022 & 2032 (%)
4.9 Neurological
4.9.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.9.2 Market Share by Region, 2022 & 2032 (%)
4.10 Diabetes Mellitus
4.10.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.10.2 Market Share by Region, 2022 & 2032 (%)
4.11 Other Diseases
4.11.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.11.2 Market Share by Region, 2022 & 2032 (%)
5 Gene Therapy R&D Market Analysis by Vector
5.1 Key Findings
5.2 Vector Segment Growth Prospects
5.3 Gene Therapy R&D Market Size Estimation and Forecast by Vector
5.4 Viral
5.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.4.3 Viral Segment Market Forecast by Type, 2022-2032 (US$ Mn)
5.4.3.1 Retrovirus
5.4.3.2 Adenovirus
5.4.3.3 AAV (Adeno-Associated Virus)
5.4.3.4 Lentivirus
5.4.3.5 Others
5.5 Non-viral
5.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.5.3 Non-viral Segment Market Forecast by Type, 2022-2032 (US$ Mn)
5.5.3.1 Naked DNA
5.5.3.2 Gene Gun
5.5.3.3 Electroporation
5.5.3.4 Lipofection
6 Gene Therapy R&D Market Analysis by Techniques
6.1 Key Findings
6.2 Techniques Segment Growth Prospects
6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques
6.4 Gene Augmentation Therapy
6.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Gene Replacement Therapy
6.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
7 Gene Therapy R&D Market Analysis by Participants
7.1 Key Findings
7.2 Participants Segment Growth Prospects
7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants
7.4 Small/Medium Pharma & Biotech
7.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 Universities & Research Institutes
7.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Hospitals, Government & Public Bodies
7.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
7.6.2 Market Share by Region, 2022 & 2032 (%)
7.7 Big Pharma
7.7.1 Market Forecast by Region, 2022-2032 (US$ Mn)
7.7.2 Market Share by Region, 2022 & 2032 (%)
8 Gene Therapy R&D Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
8.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
9 North America Gene Therapy R&D Market Analysis
9.1 Key Findings
9.2 North America Gene Therapy R&D Market Attractiveness Index
9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
9.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
9.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
9.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
9.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
9.9 U.S.
9.10 Canada
10 Europe Gene Therapy R&D Market Analysis
10.1 Key Findings
10.2 Europe Gene Therapy R&D Market Attractiveness Index
10.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
10.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
10.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
10.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
10.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
10.9 Germany
10.10 UK
10.11 France
10.12 Italy
10.13 Spain
10.14 Russia
10.15 Rest of Europe
11 Asia Pacific Gene Therapy R&D Market Analysis
11.1 Key Findings
11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index
11.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
11.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
11.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
11.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
11.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
11.9 Japan
11.10 China
11.11 India
11.12 Australia
11.13 South Korea
11.14 South East Asia
11.15 Rest of Asia Pacific
12 Latin America Gene Therapy R&D Market Analysis
12.1 Key Findings
12.2 Latin America Gene Therapy R&D Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
12.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
12.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
12.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
12.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
12.9 Brazil
12.10 Mexico
12.11 Rest of Latin America
13 MEA Gene Therapy R&D Market Analysis
13.1 Key Findings
13.2 MEA Gene Therapy R&D Market Attractiveness Index
13.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
13.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
13.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
13.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
13.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
13.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
13.9 GCC
13.10 South Africa
13.11 Rest of MEA
14 Company Profiles
14.1 Strategic Choices for Winning in Gene Therapy R&D Market
14.1.1 Diversification of Technical Risks
14.1.2 How to Achieve Long Term Benefits to Patients
14.1.3 Building Digital Capabilities
14.1.4 Mergers & Acquisitions to Offer Lucrative Growth Prospects for Players Across the Value Chain
14.2 Approved Cellular & Gene Therapy Products as of March 2021
14.3 Ongoing Gene Therapy Clinical Trials by Companies
14.4 Gene Therapy Companies Market Capitalization
14.5 Strategic Outlook
14.6 Astellas Pharma Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2015-2021
14.6.3.2 Regional Market Shares, 2020
14.6.3.3 Gross Profit, 2015-2021
14.6.3.4 R&D, 2015-2021
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 American Gene Technologies
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.7.4 Strategic Outlook
14.8 Applied Genetic
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2015-2021
14.8.3.2 Gross Profit, 2015-2021
14.8.3.3 R&D, 2015-2021
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Bayer
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2015-2021
14.9.3.2 Regional Market Shares, 2021
14.9.3.3 Gross Profit, 2015-2021
14.9.3.4 R&D, 2015-2021
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Benitec BioPharma
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2015-2021
14.10.3.2 Gross Profit, 2015-2021
14.10.3.3 R&D, 2015-2021
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 Biogen
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2015-2021
14.11.3.2 Regional Market Shares, 2021
14.11.3.3 Gross Profit, 2015-2021
14.11.3.4 R&D, 2015-2021
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Bluebird Bio
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2015-2021
14.12.3.2 Gross Profit, 2015-2019
14.12.3.3 R&D, 2015-2021
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Bristol Myers Squibb
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2015-2021
14.13.3.2 Regional Market Shares, 2021
14.13.3.3 Gross Profit, 2015-2021
14.13.3.4 R&D, 2015-2021
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Calimmune, Inc. (CSL Behiring)
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Cellectis
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2015-2021
14.15.3.2 Gross Profit, 2015-2021
14.15.3.3 R&D, 2015-2021
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 F. Hoffmann-La Roche Ltd.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2015-2021
14.16.3.2 Gross Profit, 2015-2021
14.16.3.3 R&D, 2015-2021
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 GenSight Biologics
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
14.17.4 Strategic Outlook
14.18 Gilead Lifesciences, Inc.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.3.1 Net Revenue, 2015-2021
14.18.3.2 Gross Profit, 2015-2021
14.18.3.3 R&D, 2015-2021
14.18.4 Product Benchmarking
14.18.5 Strategic Outlook
14.19 Novartis AG
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2015-2021
14.19.3.2 Regional Market Shares, 2021
14.19.3.3 Gross Profit, 2015-2021
14.19.3.4 R&D, 2015-2021
14.19.4 Product Benchmarking
14.19.5 Strategic Outlook
14.20 Orchard Therapeutics
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Product Benchmarking
14.20.4 Strategic Outlook
14.21 Oxford Biomedica
14.21.1 Company Snapshot
14.21.2 Company Overview
14.21.3 Financial Analysis
14.21.3.1 Net Revenue, 2015-2021
14.21.3.2 Regional Market Shares, 2021
14.21.4 Product Benchmarking
14.21.5 Strategic Outlook
14.22 Pfizer, Inc.
14.22.1 Company Snapshot
14.22.2 Company Overview
14.22.3 Financial Analysis
14.22.3.1 Net Revenue, 2015-2021
14.22.3.2 Regional Market Shares, 2021
14.22.3.3 Gross Profit, 2015-2021
14.22.3.4 R&D, 2015-2021
14.22.4 Product Benchmarking
14.22.5 Strategic Outlook
14.23 REGENXBIO Inc.
14.23.1 Company Snapshot
14.23.2 Company Overview
14.23.3 Financial Analysis
14.23.3.1 Net Revenue, 2015-2021
14.23.3.2 Gross Profit, 2015-2021
14.23.3.3 R&D, 2015-2021
14.23.4 Product Benchmarking
14.23.5 Strategic Outlook
14.24 Sangamo Therapeutics, Inc.
14.24.1 Company Snapshot
14.24.2 Company Overview
14.24.3 Financial Analysis
14.24.3.1 Net Revenue, 2015-2021
14.24.3.2 Gross Profit, 2015-2021
14.24.3.3 R&D, 2015-2021
14.24.4 Product Benchmarking
14.24.5 Strategic Outlook
14.25 Sanofi
14.25.1 Company Snapshot
14.25.2 Company Overview
14.25.3 Financial Analysis
14.25.3.1 Net Revenue, 2015-2021
14.25.3.2 Regional Market Shares, 2021
14.25.3.3 Gross Profit, 2015-2021
14.25.3.4 R&D, 2015-2021
14.25.4 Product Benchmarking
14.25.5 Strategic Outlook
14.26 Spark Therapeutics (Subsidiary of Roche)
14.26.1 Company Snapshot
14.26.2 Company Overview
14.26.3 Product Benchmarking
14.26.4 Strategic Outlook
14.27 Takeda Pharmaceuticals
14.27.1 Company Snapshot
14.27.2 Company Overview
14.27.3 Financial Analysis
14.27.3.1 Net Revenue, 2015-2021
14.27.3.2 Regional Market Shares, 2021
14.27.3.3 Gross Profit, 2015-2021
14.27.3.4 R&D, 2015-2021
14.27.4 Product Benchmarking
14.27.5 Strategic Outlook
14.28 Transgene
14.28.1 Company Snapshot
14.28.2 Company Overview
14.28.3 Product Benchmarking
14.28.4 Strategic Outlook
14.29 UniQure NV
14.29.1 Company Snapshot
14.29.2 Company Overview
14.29.3 Financial Analysis
14.29.3.1 Net Revenue, 2015-2021
14.29.3.2 Gross Profit, 2015-2021
14.29.3.3 R&D, 2015-2021
14.29.4 Product Benchmarking
14.29.5 Strategic Outlook
14.30 Voyager Therapeutics
14.30.1 Company Snapshot
14.30.2 Company Overview
14.30.3 Financial Analysis
14.30.3.1 Net Revenue, 2015-2021
14.30.3.2 Gross Profit, 2015-2021
14.30.3.3 R&D, 2015-2021
14.30.4 Product Benchmarking
14.30.5 Strategic Outlook
14.31 ViGeneron
14.31.1 Company Snapshot
14.31.2 Company Overview
14.31.3 Product Benchmarking
14.31.4 Strategic Outlook
14.32 GeneQuine Biotherapeutics
14.32.1 Company Snapshot
14.32.2 Company Overview
14.32.3 Product Benchmarking
14.32.4 Strategic Outlook
14.33 OCUGEN, INC.
14.33.1 Company Snapshot
14.33.2 Company Overview
14.33.3 Product Benchmarking
14.33.4 Strategic Outlook
14.34 Taysha GTx
14.34.1 Company Snapshot
14.34.2 Company Overview
14.34.3 Product Benchmarking
14.34.4 Strategic Outlook
14.35 Sarepta Therapeutics, Inc.
14.35.1 Company Snapshot
14.35.2 Company Overview
14.35.3 Product Benchmarking
14.35.4 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks from
15.2 Recommendations for Market Players
List of Tables
Table 1 Gene Therapy R&D Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
Table 2 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Gene Therapy Pipeline: Q1-Q4, 2022
Table 7 Gene Therapy Pipeline: Q1-Q4, 2023
Table 8 Gene Therapy Pipeline: Q1-Q4, 2024
Table 9 Gene Therapy Pipeline: Q1-Q4, 2025
Table 10 Gene Therapy Pipeline Assets Forecast till 2026 (US$ mn)
Table 11 Global Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 12 Cancer Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 13 Rare Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 14 Global Gene Therapy R&D Market Forecast by Rare Diseases, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 15 Cardiovascular Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 16 Ophthalmic Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 17 Hematology Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 18 Neurological Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 19 Diabetes Mellitus Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 20 Other Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 21 Global Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 22 Viral Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 23 Global Gene Therapy R&D Market Forecast by Viral Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 24 Viral Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 25 Global Gene Therapy R&D Market Forecast by Non-viral, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 26 Global Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 27 Gene Augmentation Therapy Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 28 Gene Replacement Therapy Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 29 Global Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 30 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 31 Universities & Research Institutes Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 32 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 33 Big Pharma Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 34 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 35 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 36 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 37 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 38 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 39 North America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 40 North America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 41 North America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 42 North America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 43 North America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 44 U.S. Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 45 Canada Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 46 Europe Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 47 Europe Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 48 Europe Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 49 Europe Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 50 Europe Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 51 Germany Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 52 UK Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 53 France Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 54 Italy Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 55 Spain Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 56 Russia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 57 Rest of Europe Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 58 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 59 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 60 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 61 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 62 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 63 Japan Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 64 China Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 65 India Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 66 Australia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 67 South Korea Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 68 South East Asia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 69 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 70 Latin America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 71 Latin America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 72 Latin America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 73 Latin America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 74 Latin America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 75 Brazil Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 76 Mexico Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 77 Rest of Latin America Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 78 MEA Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 79 MEA Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 80 MEA Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 81 MEA Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 82 MEA Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 83 GCC Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 84 South Africa Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 85 Rest of MEA Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 86 Gene Therapy R&D Market Strategic Outlook
Table 87 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Astellas Pharma Inc.: Product Benchmarking
Table 89 American Gene Technologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 American Gene Technologies: Product Benchmarking
Table 91 Applied Genetic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Applied Genetic: Product Benchmarking
Table 93 Applied Genetic: Strategic Outlook
Table 94 Bayer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Bayer: Product Benchmarking
Table 96 Bayer: Strategic Outlook
Table 97 Benitec BioPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Benitec BioPharma: Product Benchmarking
Table 99 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Biogen: Product Benchmarking
Table 101 Biogen: Strategic Outlook
Table 102 Bluebird Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Bluebird Bio: Product Benchmarking
Table 104 Bluebird Bio: Strategic Outlook
Table 105 Bristol Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Bristol Myers Squibb: Product Benchmarking
Table 107 Bristol Myers Squibb: Strategic Outlook
Table 108 Calimmune, Inc. (CSL Behiring): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Calimmune, Inc. (CSL Behiring): Product Benchmarking
Table 110 Calimmune, Inc. (CSL Behiring): Strategic Outlook
Table 111 Cellectis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Cellectis: Product Benchmarking
Table 113 Cellectis: Strategic Outlook
Table 114 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 116 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 117 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 GenSight Biologics: Product Benchmarking
Table 119 Gilead Lifesciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Gilead Lifesciences, Inc.: Product Benchmarking
Table 121 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Novartis AG: Product Benchmarking
Table 123 Novartis AG: Strategic Outlook
Table 124 Orchard Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Orchard Therapeutics: Product Benchmarking
Table 126 Orchard Therapeutics: Strategic Outlook
Table 127 Oxford Biomedica: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Oxford Biomedica: Product Benchmarking
Table 129 Oxford Biomedica: Strategic Outlook
Table 130 Pfizer, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Pfizer, Inc.: Product Benchmarking
Table 132 Pfizer, Inc.: Strategic Outlook
Table 133 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 REGENXBIO Inc.: Product Benchmarking
Table 135 REGENXBIO Inc.: Strategic Outlook
Table 136 Sangamo Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Sangamo Therapeutics, Inc.: Product Benchmarking
Table 138 Sangamo Therapeutics, Inc.: Strategic Outlook
Table 139 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Sanofi: Product Benchmarking
Table 141 Sanofi: Strategic Outlook
Table 142 Spark Therapeutics (Subsidiary of Roche): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Spark Therapeutics (Subsidiary of Roche): Product Benchmarking
Table 144 Spark Therapeutics (Subsidiary of Roche): Strategic Outlook
Table 145 Takeda Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Takeda Pharmaceuticals: Product Benchmarking
Table 147 Takeda Pharmaceuticals: Strategic Outlook
Table 148 Transgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Transgene: Product Benchmarking
Table 150 UniQure NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 151 UniQure NV: Product Benchmarking
Table 152 UniQure NV: Strategic Outlook
Table 153 Voyager Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 154 Voyager Therapeutics: Product Benchmarking
Table 155 Voyager Therapeutics: Strategic Outlook
Table 156 ViGeneron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 157 ViGeneron: Product Benchmarking
Table 158 ViGeneron: Strategic Outlook
Table 159 GeneQuine Biotherapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 160 GeneQuine Biotherapeutics: Product Benchmarking
Table 161 GeneQuine Biotherapeutics: Strategic Outlook
Table 162 OCUGEN, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 163 OCUGEN, INC.: Product Benchmarking
Table 164 OCUGEN, INC.: Strategic Outlook
Table 165 Taysha GTx: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 166 Taysha GTx: Product Benchmarking
Table 167 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 168 Sarepta Therapeutics, Inc.: Product Benchmarking
Table 169 Sarepta Therapeutics, Inc.: Strategic Outlook
List of Figures
Figure 1 Gene Therapy R&D Market Segmentation
Figure 2 Gene Therapy R&D Market by Disease: Market Attractiveness Index
Figure 3 Gene Therapy R&D Market by Vector: Market Attractiveness Index
Figure 4 Gene Therapy R&D Market by Techniques: Market Attractiveness Index
Figure 5 Gene Therapy R&D Market by Participants: Market Attractiveness Index
Figure 6 Gene Therapy R&D Market Attractiveness Index by Region
Figure 7 Gene Therapy R&D Market: Market Dynamics
Figure 8 Gene, Cell & Tissue Bases Therapeutic Developers Financings by Deal Type, 2021
Figure 9 Gene, Cell & Tissue Bases Therapeutic Developers Financings by Deal Type, 2020
Figure 10 Rare vs. Prevalent: Industry Sponsored Trials
Figure 11 Rare vs. Prevalent: Academic & Government Sponsored Trials
Figure 12 COVID Impact Analysis: Gene Therapy R&D Market Recovery Scenarios
Figure 13 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 14 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 15 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 16 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 17 Gene Therapy R&D Marke
